Inotuzumab ozogamicin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD22 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
635715-01-4  |
| ChemSpider | none |
| UNII |
P93RUU11P7 |
| KEGG |
D08933  |
| Chemical and physical data | |
| Formula | C6518H10002N1738O2036S42 |
| Molar mass | 150,000 g/mol |
| (what is this?) (verify) | |
Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers.[1] It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).[2]
This drug is being developed by Pfizer and UCB.
It has undergone numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL). [3]
A Phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility.[4]
As of April 2016 ten clinical trials were active (including one phase III for Acute Lymphoblastic Leukemia (ALL)[5]), six still recruiting.[3]
See also
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Inotuzumab ozogamicin, American Medical Association.
- ↑ Takeshita, A; Shinjo, K; Yamakage, N; Ono, T; Hirano, I; Matsui, H; Shigeno, K; Nakamura, S; Tobita, T; Maekawa, M (2009). "CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.". British journal of haematology. 146 (1): 34–43. doi:10.1111/j.1365-2141.2009.07701.x. PMID 19388933.
- 1 2 http://clinicaltrials.gov/ct2/results?term=Inotuzumab+ozogamicin
- ↑ Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility. May 2013
- ↑ An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)